The Underutilization, Adverse Reactions and Efficacy of Statins after Liver Transplant: A Meta-Analysis and Systematic Review

• Published in: Transplantology (Basel, Switzerland) Vol. 2; no. 3; pp. 264 - 273
• Main Authors: Ho, Yeung Jek, Koh, Audrey Su-Min, Ong, Zhi Hao, Ng, Cheng Han, Kong, Gwyneth, Chew, Nicholas W.S., Lim, Hui Ning, Siddiqui, M. Shadab, Muthiah, Mark Dhinesh
• Format: Journal Article
• Language: English
• Published: Birmingham MDPI AG 01.09.2021
• Subjects: Cardiovascular disease; Cholesterol; Diabetes; graft rejection; hyperlipidemia; Lipids; Liver transplants; Meta-analysis; Metabolic disorders; Mortality; Muscle pain; post-liver transplant; statin; Statins; Statistical analysis; United States > US
• DOI: 10.3390/transplantology2030025
• ISSN: 2673-3943

(1) Background: Treatment of dyslipidemia via statin therapy in the non-liver transplant (LT) population is associated with a mortality benefit; however, the impact of statin therapy in post-LT population is not well-defined. This meta-analysis seeks to investigate the safety and efficacy of statin therapy in post-LT patients. (2) Methods: A systematic literature search on Medline and EMBASE database was conducted. A single-arm proportional meta-analysis and conventional pair-wise meta-analysis were performed to compare different outcomes with a random effects model. (3) Results: A total of 11 studies were included in this study, with 697 LT recipients identified to be on statin therapy. Statins were underutilized with only 32% (95% CI: 0.15–0.52) of 1094 post-LT patients on therapy. The incidence of adverse events of 14% (95% CI: 0.05–0.25) related to statin therapy was low. A significant mortality benefit was noted in patients on statin therapy with HR = 0.282 (95% CI: 0.154–0.517, p < 0.001), and improved lipid profiles post LT. The use of statins also significantly decreased odds of graft rejection (OR = 0.33; 95% CI: 0.15–0.73) and hepatocellular carcinoma (HCC) recurrence (HR = 0.32, 95% CI: 0.11–0.89). (4) Conclusions: Statin therapy is safe and efficacious in post-LT patients. Future studies to evaluate the effects of interactions between statins and immunosuppressant therapy are warranted.